Ciprofloxacin and norfloxacin for selective decontamination in patients with severe granulocytopenia.
In a randomized multicenter study, ciprofloxacin and norfloxacin, each in two different dose regimens and in combination with non-absorbable antimycotics, were administered to 51 patients with acute leukaemia undergoing aggressive remission induction chemotherapy for infection prevention. Both drugs showed an effective elimination of gram-negative potential pathogens and Staphylococcus aureus not affecting the anaerobic flora of the gastrointestinal tract. A low incidence of side effects and a satisfactory patient compliance could be observed. A daily dosage of 1,000 mg ciprofloxacin or 800 mg norfloxacin is recommended for infection prevention in severely granulocytopenic patients.
Maschmeyer
G
G
Department of Internal Medicine, Haematology and Oncology, Evangelisches Krankenhaus, Essen-Werden.
Haralambie
E
E
Gaus
W
W
Kern
W
W
Dekker
A W
AW
De Vries-Hospers
H G
HG
Sizoo
W
W
König
W
W
Gutzler
F
F
Daenen
S
S
D000208:Acute Disease; D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001424:Bacterial Infections / Q000517:prevention & control*; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D009643:Norfloxacin / Q000008:administration & dosage / Q000627:therapeutic use*; D010865:Pilot Projects; D011897:Random Allocation; D012074:Remission Induction
D002939:Ciprofloxacin; D009643:Norfloxacin